Nasolacrimal drainage system implants for drug therapy
An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
1. An implant for insertion through a punctum and into a canalicular lumen of a patient, the implant comprising:
a plug body comprising a drug insert;
the drug insert comprising:
a matrix of material;
a therapeutic agent dispersed in the matrix of material; and
a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen, wherein when the implant is inserted into the canalicular lumen an exposed surface of the drug insert is in direct contact with tear fluid to allow diffusion of the therapeutic agent from a surface of the matrix of material to a tear film; and
a retention structure configured to retain the implant within the canalicular lumen.
2. The implant according to claim 1 , wherein the retention structure is configured to engage a luminal wall of the canalicular lumen to retain the implant within the canalicular lumen.
3. The implant according to claim 1 , wherein the retention structure is an extension configured to wedge the implant in the canalicular lumen to prevent migration of the implant.
4. The implant according to claim 1 , wherein the retention structure comprises a shape memory polymer.
5. The implant according to claim 1 , wherein the retention structure comprises a fluid swellable material.
6. The implant according to claim 5 , wherein the fluid swellable material comprises a hydrogel.
7. The implant according to claim 1 , wherein the therapeutic agent comprises a prostaglandin analogue.
8. The implant according to claim 7 , wherein the prostaglandin analogue is selected from the group consisting of latanoprost, bimatoprost, and travoprost.
9. The implant according to claim 1 , wherein the matrix of material comprises a non-biodegradable polymer.
10. The implant according to claim 9 , wherein the matrix of material comprises silicone or urethane.
11. An implant for insertion into a punctum of a patient, the implant comprising:
a therapeutic agent;
a body of material that holds the therapeutic agent; and
an expandable retention structure disposed over at least a portion of the body of material, the expandable retention structure configured to retain the body of material near the punctum.
12. The implant according to claim 11 , wherein the body of material holds the therapeutic agent in a reservoir and/or a matrix.
13. The implant according to claim 12 , wherein the body of material is a matrix comprising a non-biodegradable polymer.
14. The implant according to claim 13 , wherein the matrix comprises silicone or urethane.
15. The implant according to claim 11 , wherein the therapeutic agent comprises a prostaglandin analogue.
16. The implant according to claim 15 , wherein the prostaglandin analogue is selected from the group consisting of latanoprost, bimatoprost, and travoprost.
17. The implant according to claim 11 , wherein the expandable retention structure comprises a shape memory polymer.
18. The implant according to claim 11 , wherein the expandable retention structure comprises a fluid swellable material.
19. The implant according to claim 18 , wherein the fluid swellable material comprises a hydrogel.
20. The implant according to claim 11 , wherein the retention structure is configured to engage a luminal wall of the canalicular lumen to retain the implant within the canalicular lumen.